Phase 1 Dose-Determining Study of EXS73565 in Patients with Relapsed or Refractory B-Cell Malignancies Including CLL, MCL, DLBCL, FL, and MZL

The primary objective of this study is to determine the appropriate dose of **EXS73565** in participants with **relapsed or refractory B-cell malignancies**. These malignancies include chronic lymphocytic leukemia (CLL), Richter’s Transformation (RT) from CLL, mantle-cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL). Establishing the correct dosage is clinically significant as it aims to optimize therapeutic efficacy while minimizing potential adverse effects in this patient population.

The clinical trial involves a total of **25 participants** diagnosed with **relapsed or refractory B-cell malignancies**, including chronic lymphocytic leukemia (CLL), Richter’s Transformation from CLL, mantle-cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL). The study population comprises both male and female subjects, with an age range that includes adults and older adults. Participants were selected based on specific criteria, although detailed inclusion or exclusion criteria were not provided. The trial includes a vulnerable population, indicating that special considerations may be necessary for their participation. Lifestyle factors such as diet, physical activity, or habits were not specified in the available data.

The clinical trial is a **Phase 1** study designed to determine the appropriate dosage of EXS73565 in participants with **relapsed or refractory B-cell malignancies**, including chronic lymphocytic leukemia (CLL), Richter's Transformation from CLL, mantle-cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL). The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from February 1, 2025, to December 2, 2027, encompassing both recruitment and follow-up periods.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve comprehensive medical evaluations and laboratory tests to confirm the diagnosis and ensure the absence of exclusion criteria. Following successful screening, participants will be randomized to receive either the investigational product or a control, with neither the participants nor the investigators aware of the group assignments, maintaining the double-blind nature of the study.

Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' health status, assess the safety and efficacy of the treatment, and adjust dosages as necessary. These visits will include physical examinations, laboratory tests, and assessments of disease progression. The end-of-study visit will mark the conclusion of the participant's involvement, during which final evaluations will be conducted to gather comprehensive data on the treatment's impact.

The expected length of participant involvement will vary depending on individual response to treatment and disease progression, but it is anticipated to last throughout the trial's duration unless early termination is warranted. Conditions that may lead to early termination include adverse events, disease progression, or withdrawal of consent by the participant. The trial is structured to ensure participant safety and the collection of robust data to inform future research and potential therapeutic applications.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating its primary focus on safety and dosage rather than efficacy. However, any preliminary efficacy data collected will be analyzed to inform future studies. The trial is scheduled to commence recruitment on February 1, 2025, with an estimated completion date of December 2, 2027. Specific efficacy endpoints, methods, and tools for assessment are not detailed in the available data. The trial will adhere to standard protocols for data collection and analysis, ensuring that any efficacy-related findings are systematically documented and evaluated.